Vaxcyte (PCVX) Operating Leases (2021 - 2026)
Vaxcyte (PCVX) posted quarterly Operating Leases of $116.3 million for Q1 2026, up 43.43% year-over-year from $81.1 million in Q1 2025, and up 4.34% quarter-over-quarter from $111.5 million in Q4 2025.
Vaxcyte (PCVX) Operating Leases (2021 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Operating Leases for 6 consecutive years, with $116.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases rose 43.43% year-over-year to $116.3 million; the TTM figure through Mar 2026 stood at $116.3 million (up 43.43% YoY), while the FY2025 annual figure was $111.5 million, up 70.9% from the prior year.
- Operating Leases rose to $116.3 million in Q1 2026 per PCVX's latest filing, from $111.5 million in the prior quarter.
- Across five years, Operating Leases topped out at $116.3 million in Q1 2026 and bottomed at $7.8 million in Q3 2023.
- Historically, Operating Leases has averaged $41.3 million across 5 years, with a median of $18.3 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Leases jumped 6371.11% — and 2023, when it plunged 41.74%.
- Vaxcyte's Operating Leases stood at $12.9 million in 2022, then soared by 71.4% to $22.1 million in 2023, then jumped by 194.96% to $65.2 million in 2024, then jumped by 70.9% to $111.5 million in 2025, then increased by 4.34% to $116.3 million in 2026.
- Business Quant data shows PCVX's Operating Leases at $116.3 million in Q1 2026, $111.5 million in Q4 2025, and $78.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.45 Mn |
| Mar 31, 2026 | 116.30 Mn |
| Dec 31, 2025 | 111.46 Mn |
| Sep 30, 2025 | 78.67 Mn |
| Jun 30, 2025 | 85.85 Mn |
| Mar 31, 2025 | 81.08 Mn |
| Dec 31, 2024 | 65.22 Mn |
| Sep 30, 2024 | 18.32 Mn |
| Jun 30, 2024 | 18.29 Mn |
| Mar 31, 2024 | 20.22 Mn |
| Dec 31, 2023 | 22.11 Mn |
| Sep 30, 2023 | 7.78 Mn |
| Jun 30, 2023 | 9.22 Mn |
| Mar 31, 2023 | 10.64 Mn |
| Dec 31, 2022 | 12.90 Mn |
| Sep 30, 2022 | 13.36 Mn |
| Jun 30, 2022 | 14.56 Mn |
| Mar 31, 2022 | 15.83 Mn |
| Dec 31, 2021 | 12.90 Mn |
| Sep 30, 2021 | 553,000.00 |